Hot Promising Companies To Watch In Right Now: MannKind Corporation(MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States, Europe, and Asia. Its lead product candidate, AFREZZA Inhalation Powder, an ultra rapid-acting insulin that is in Phase III clinical trials for the treatment of diabetes for the control of hyperglycemia. The company also develops MKC1106-MT, an investigational cancer immunotherapy product, which is in Phase II clinical trials for the treatment of adults with type 1 or type 2 diabetes; and MKC204, which is in preclinical development stage for the treatment of malignancies and inflammatory diseases. In addition, its products include MKC253 (GLP-1), a Phase I clinical trials product for the treatment of type 2 diabetes; MKC1106-PP, a Phase I clinical trials product for diverse tumor types, metastatic disease, and/or progressive and refractory disease; and MKC180, an obesity compound and MKC1106-NS , a cancer immunotherapy product that are in preclinical trials. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
MannKind (NASDAQ: MNKD) shares shot up 79.10 percent to $7.20 after the company confirmed that the FDA Advisory Committee recommended the approval of the company's diabetes drug AFREZZA. - [By Brian Orelli]
Last clinical trials!
MannKind (NASDAQ: MNKD ) has been developing its inhaled insulin product Afrezza for years. The FDArejectedthe drug-device combo in 2010, requesting additional information on the clinical utility of Afrezza.
source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-promising-companies-to-watch-in-right-now-2.html
No comments:
Post a Comment